ClinicalTrials.gg
TerminatedNCT01714817Updated Feb 26, 2021Results posted

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

A Phase 3 interventional study of BMS-188667 and Mycophenolate mofetil in Lupus Nephritis, sponsored by Bristol-Myers Squibb. Terminated at 149 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Inability to meet protocol objectives.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
695
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
2nd of 100
695 · median 50
Started
2013
with 5 others
Phase 3
16 of 114
2 open now
Registered
22nd of 114
by date
Lead sponsor
3 of 114
Bristol-Myers Squibb

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 2nd largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 22nd registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)

03

Conditions studied

  • Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For additional information please contact the BMS Lupus Nephritis Clinical Trial Matching Service at 855-56-LUPUS. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.

Note: Subjects > 16 are eligible for enrollment at selected centers

Inclusion criteria

Inclusion Criteria:

  • Potential subjects must have active lupus nephritis
  • within 12 months prior to screening visit indicating active Class 3 or 4 proliferative lupus glomerulonephritis (lupus effecting your kidney)
  • Urine protein creatinine ratio (UPCR) ≥ 1 at Screening
  • Serum creatinine ≤ 3 mg/dL (ie, ≤ 265 micromol/L)
  • There must also be evidence of active disease within 3 months of Screening, based on at least one of the following:

    • Worsening of lupus nephritis OR
    • UPCR ≥ 3 at Screening OR
    • Active urine sediment OR
    • Biopsy within 3 months prior to screening visit indicating active Class 3 or Class 4 active proliferative lupus glomerulonephritis

Inclusion Criteria for the Long-Term Extension Period:

  • Signed Written
  • Subjects who achieve a complete or partial renal response after completing 2 years of double-blind treatment

Exclusion criteria

Exclusion Criteria:

  • Systemic Lupus Erythematosus (SLE) must be the primary/main diagnosis
  • Current symptoms of severe, progressive, or uncontrolled non-SLE related renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease, or other concomitant medical conditions that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study
  • Significant active Central nervous system (CNS) lupus with the exception of fatigue or mild stable cognitive
  • Subjects who are diagnosed as end-stage renal disease or whose kidney damage is too significant and irreversible
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
695 participants (actual)

Study arms

  • Experimental
    BMS-188667 + Mycophenolate mofetil + Prednisone

    BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks

    Biological: BMS-188667 · Drug: Mycophenolate mofetil · Drug: Prednisone

  • Placebo comparator
    Placebo + Mycophenolate mofetil + Prednisone

    Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks

    Drug: Mycophenolate mofetil · Drug: Prednisone · Biological: Placebo matching with BMS-188667

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Complete Renal Response (CR) of Lupus Glomerulonephritis at Day 365 of the Double-blind Period

    Number of participants achieving CR was divided by the total number of participants in that arm and expressed as a percentage. CR defined as: eGFR is normal or no \<85% of the baseline; eGFR based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equiv. for at least 28 days prior to assessment. Participants with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as having achieved CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use (Yes/No), race (Asian/ Black/Caucasian/Other) and baseline UPCR as a continuous variable.

    Time frame: Day 365

Secondary outcomes

  1. Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 365 of the Double-blind Period

    Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.

    Time frame: Day 365

  2. Adjusted Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 365 of the Double-blind Period in Nephrotic Participants

    Adjusted Mean Change from Baseline in UPCR at Day 365 of the double-blind period in nephrotic participants

    Time frame: Baseline and Day 365

  3. Adjusted Mean Change From Baseline in UPCR at Day 365 of the Double-blind Period in Overall Population

    Adjusted Mean Change from Baseline in Urine protein/creatinine ratio (UPCR) at Day 365 of the double-blind period in the overall population

    Time frame: Day 1 and Day 365

  4. Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During Year 1 of the Double-blind Period

    Adjusted mean change from baseline in British Isles Lupus Assessment Group (BILAG) score over time during Year 1 of the double-blind period based on a repeated measure mixed model and presented at each visit in the first 12-month of the double-blind period. BILAG index measures disease activity in different organs/systems separately. BILAG score is calculated for each of 9 systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. BILAG "A" represents the presence of serious features of lupus. BILAG "B" represents more moderate features of the disease. BILAG "C" includes only mild symptomatic features. BILAG "D" represents prior activity with no current symptoms due to active lupus. BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.

    Time frame: Day 1 to Day 365

  5. Number of Participants With Any Adverse Events (AEs) During Year 1 of the Double-blind Period

    All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.

    Time frame: From Day 1 up to 56 days post last dose in Year 1 of the double-blind period

  6. Percentage of Participants With Ranked Outcome of Complete Renal Response, Partial Renal Response (PR), and No Renal Response (NR) During the Double-blind Period

    Complete Renal Response or Complete Response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; UPCR \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment. Partial Renal Response or Partial Response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was greater than or equal to 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment. No Renal Response or No Response (NR): defined as not meeting criteria for CR or PR or withdrawn

    Time frame: Day 365, Day 729

  7. Median Time to Complete Renal Response During the Double-blind Period in All Participants

    The estimate of median time to Complete Renal Response is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.

    Time frame: Day 365, Day 729

  8. Median Time to Complete Renal Response During the Double-blind Period in Nephrotic Participants

    The estimate of median time to Complete Renal Response in nephrotic participants is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.

    Time frame: Day 365, Day 729

  9. Median Time to Partial Renal Response During the Double-blind Period in All Participants

    The estimate of median time to Partial Response (PR) is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment

    Time frame: Day 365, Day 729

  10. Median Time to Partial Renal Response During the Double-blind Period in Nephrotic Participants

    The estimate of median time to Partial Response (PR) in nephrotic participants is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment

    Time frame: Day 365, Day 729

  11. Adjusted Mean Change From Baseline in UPCR Over Time

    A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used.

    Time frame: Day 365; Day 729, includes data up to July 1st 2017 when double-blind therapy ended

  12. Median Percent Change From Baseline in UPCR Over Time

    A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used. % Change from Baseline = (post baseline - baseline value) / baseline value x 100

    Time frame: Day 365, Day 729

  13. Adjusted Mean Change From Baseline in eGFR Over Time

    Estimated glomerular filtration rate(eGFR), will be calculated by the CKD-EPI formula shown below.50 eGFR is expressed as mL/min per 1.73m2. For the purpose of this study lower limit of normal eGFR is defined as 90mL/min per 1.73m2 eGFR = 141 X min (Scr/k, 1)α X max (Scr/k, 1)-1.209 X 0.993Age X (1.018 \[if female\]) X (1.159 \[if black\]) Where Scr is serum creatinine (mg/dL), k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1, age in years.

    Time frame: Day 365, Day 729

  14. Median Time to First Sustained Change to No Response During the Double-blind Period

    Sustained response defined as response present at 2 consecutive visits approximately 4 weeks apart. No renal response (NR): defined as not meeting criteria for CR or PR or withdrawn The estimate of median time is based on Kaplan-Meier analysis

    Time frame: Day 365, Day 729

  15. Number of Participants With Sustained Change From Higher Level of Response to no Response During the Double-blind Period

    Sustained change to no response is defined as going from CR (or PR) to NR and remaining in NR for at least 2 consecutive visits; visits should be approximately 4 weeks apart. This analysis will be based on time from response CR (or PR) to the first visit in which the no response (NR) was achieved and sustained to the next visit.

    Time frame: Day 365, Day 729

  16. Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During the Double-blind Period

    BILAG index measures and reports disease activity in different organs/systems separately. The BILAG score is calculated for each of nine systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. A BILAG "A" represents the presence of one or more serious features of lupus. A BILAG "B" represents more moderate features of the disease. A BILAG "C" includes only mild symptomatic features. A BILAG "D" represents only prior activity with no current symptoms due to active lupus. A BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.

    Time frame: Day 1 to Day 729; Day 365 to Day 729

  17. Cmin (ug/mL): Trough Level Serum Concentration of Abatacept Prior to the Administration of the IV Infusion

    Trough level serum concentration of abatacept prior to the administration of the IV infusion on Days 1 to 365

    Time frame: Days 1 to 365

  18. Cmax: Maximum Observed Serum Concentration Following Participants Receiving Active Abatacept IV

    Cmax: Maximum observed serum concentration following participants receiving active abatacept IV

    Time frame: at 1 hour post Day 1 dose and 30 minutes post Day 337 dose

  19. AUC (TAU): Area Under the Serum Concentration Time Curve Over a Dosing Interval

    AUC (TAU): Area under the serum concentration time curve over a dosing interval between Days 337 to 365.

    Time frame: Days 337 to 365

  20. Summary Statistics for Systolic Blood Pressure

    Summary statistics for systolic blood pressure

    Time frame: Day 1 to Day 729

  21. Summary Statistics for Diastolic Blood Pressure

    Summary statistics for diastolic blood pressure

    Time frame: Day 1 to Day 729

  22. Summary Statistics for Heart Rate

    Summary statistics for Heart Rate

    Time frame: Day 1 to Day 729

  23. Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (U/L)

    Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Day 729

  24. Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (g/L)

    Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Day 729

  25. Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Percentage of Blood)

    Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Day 729

  26. Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Umol/L)

    Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Day 729

  27. Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (mmol/L)

    Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Day 729

  28. Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (x10^9 Cells/L)

    Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Day 729

  29. Number of Participants With Marked Hematology Laboratory Abnormalities During Year 1 of the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier

  30. Number of Participants With Marked Liver and Kidney Function Laboratory Abnormalities During Year 1 of the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier

  31. Number of Participants With Marked Electrolyte Laboratory Abnormalities During Year 1 of the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier

  32. Number of Participants With Marked Urinalysis Laboratory Abnormalities During Year 1 of the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4

    Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier

  33. Number of Participants With Other Marked Chemistry Laboratory Abnormalities During Year 1 of the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier

  34. Number of Participants With Any Adverse Events (AEs) During Year 2 of the Double-blind Period and Long-term Extension

    All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.

    Time frame: From the first dose in Year 2 of the double-blind period up to 56 days post last dose

  35. Percentage of Participants in Treatment Failure Over Time During the Double-blind Period

    Lupus treatment failure is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor.

    Time frame: Day 365, Day 729

  36. Median Time to First Treatment Failure and Overall Treatment Failure During the Double-blind Period

    First treatment failure (or Lupus treatment failure) is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor. The hazard ratio is estimated using the Cox proportional hazards model which includes treatment group, stratification variables (baseline ACEis/ARBs use, RACE) and baseline UPCR. The estimate of median time is based on Kaplan-Meier analysis

    Time frame: Day 365, Day 729

  37. Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period

    Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.

    Time frame: Day 729

  38. Percentage of Participants in Overall Population in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period

    Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.

    Time frame: Day 729

  39. Number of Participants With Marked Hematology Laboratory Abnormalities in the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 729

  40. Number of Participants With Marked Liver and Kidney Function Laboratory Abnormalities in the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 729

  41. Number of Participants With Marked Electrolyte Laboratory Abnormalities in the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 729

  42. Number of Participants With Marked Urinalysis Laboratory Abnormalities in the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4

    Time frame: Day 1 to Day 729

  43. Number of Participants With Other Marked Chemistry Laboratory Abnormalities in the Double Blind Period

    LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte

    Time frame: Day 1 to Day 729

  44. Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period

    Participants who experienced a positive antibody response relative to baseline (ECL Assay)

    Time frame: Day 365, Day 729

07

Results

Posted Dec 21, 2017
Limitations and caveats
Study terminated early after review of Year 1 data. Only Year 2/LTE data captured within blind was analyzed. Outcomes related to renal responses were not calculated due to lack of data caused by the early termination.

Participant flow

Year 1 Period
Participant flow — Year 1 Period
MilestoneAbatacept IVPlacebo IV
Started203203
Treated202203
Completed155161
Not completed4842
Withdrew: Lack of efficacy119
Withdrew: Adverse event2017
Withdrew: Withdrawal by subject67
Withdrew: Death11
Withdrew: Lost to follow-up02
Withdrew: Poor / non-compliance01
Withdrew: Pregnancy20
Withdrew: Participant no longer meets criteria62
Withdrew: Not treated- received ace inhibition10
Withdrew: Change in concomitant medication01
Withdrew: Need of use of prohibited medications10
Withdrew: Antiproteinuric changed/dose increased01
Withdrew: Hypersensitivity to the medication01
Year 2 Period
Participant flow — Year 2 Period
MilestoneAbatacept IVPlacebo IV
Started155161
Completed129123
Not completed2638
Withdrew: Lack of efficacy412
Withdrew: Adverse event76
Withdrew: Participant request to stop treatment44
Withdrew: Administrative reason by sponsor43
Withdrew: Participant withdrew consent15
Withdrew: Participant no longer meets criteria14
Withdrew: Lost to follow-up20
Withdrew: Participant went to us stopped treatment01
Withdrew: Pregnancy11
Withdrew: Completed year 1, did not enter year 221
Withdrew: Given cyclophosphamide, corticosteroids01
Long-Term Extension (LTE) Period
Participant flow — Long-Term Extension (LTE) Period
MilestoneAbatacept IVPlacebo IV
Started129123
Completed6253
Not completed6770
Withdrew: Administrative reason by sponsor2721
Withdrew: Disease progression14
Withdrew: Not effective01
Withdrew: Participant request to stop treatment11
Withdrew: Participant withdrew consent11
Withdrew: Adverse event unrelated to study drug10
Withdrew: Lost to follow-up01
Withdrew: Pregnancy10
Withdrew: Study drug toxicity10
Withdrew: Participant no longer meets criteria10
Withdrew: Completed year 2, did not enter lte3338
Withdrew: Absence of renal response01
Withdrew: Investigator decision, study termination01
Withdrew: Study was terminated01

Outcome measures

PrimaryPercentage of Participants in Complete Renal Response (CR) of Lupus Glomerulonephritis at Day 365 of the Double-blind Period

Number of participants achieving CR was divided by the total number of participants in that arm and expressed as a percentage. CR defined as: eGFR is normal or no \<85% of the baseline; eGFR based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equiv. for at least 28 days prior to assessment. Participants with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as having achieved CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use (Yes/No), race (Asian/ Black/Caucasian/Other) and baseline UPCR as a continuous variable.

Time frame:
Day 365
Reported as:
Number · Percentage
Percentage of Participants in Complete Renal Response (CR) of Lupus Glomerulonephritis at Day 365 of the Double-blind Period
PercentageAbatacept IVPlacebo IV
Percentage of Participants in Complete Renal Response (CR) of Lupus Glomerulonephritis at Day 365 of the Double-blind Period35.1 (0.8967 to 1.5726)33.5
Statistical analysis
  • Abatacept IV vs Placebo IV · Stratified logistic regression · p = 0.7264 · Odds ratio (or): 1.08 · 95% CI 0.7077 to 1.6421Abatacept IV:Placebo IV 95%CI for Odds Ratio
SecondaryPercentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 365 of the Double-blind Period

Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.

Time frame:
Day 365
Reported as:
Number · Percentage
Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 365 of the Double-blind Period
PercentageAbatacept IVPlacebo IV
Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 365 of the Double-blind Period27 (0.8967 to 1.5726)29.5
Statistical analysis
  • Abatacept IV vs Placebo IV · Odds ratio (or): 0.81 · 95% CI 0.4148 to 1.5956Abatacept IV:Placebo IV
SecondaryAdjusted Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 365 of the Double-blind Period in Nephrotic Participants

Adjusted Mean Change from Baseline in UPCR at Day 365 of the double-blind period in nephrotic participants

Time frame:
Baseline and Day 365
Reported as:
Mean · UPCR (mg/mg)
Adjusted Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 365 of the Double-blind Period in Nephrotic Participants
UPCR (mg/mg)Abatacept IVPlacebo IV
Adjusted Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 365 of the Double-blind Period in Nephrotic Participants-5.01 ± 0.33-4.84 ± 0.35
Statistical analysis
  • Abatacept IV vs Placebo IV · Mixed Models Analysis · p = 0.571 · Adjusted mean difference: -0.17 · 95% CI -0.76 to 0.42Adjusted mean difference from placebo
SecondaryAdjusted Mean Change From Baseline in UPCR at Day 365 of the Double-blind Period in Overall Population

Adjusted Mean Change from Baseline in Urine protein/creatinine ratio (UPCR) at Day 365 of the double-blind period in the overall population

Time frame:
Day 1 and Day 365
Reported as:
Mean · UPCR (mg/mg)
Adjusted Mean Change From Baseline in UPCR at Day 365 of the Double-blind Period in Overall Population
UPCR (mg/mg)Abatacept IVPlacebo IV
Adjusted Mean Change From Baseline in UPCR at Day 365 of the Double-blind Period in Overall Population-2.99 ± 0.17-2.90 ± 0.16
Statistical analysis
  • Abatacept IV vs Placebo IV · Mixed Models Analysis · p = 0.561 · Adjusted mean difference: -0.09 · 95% CI -0.41 to 0.22Adjusted mean difference from placebo
SecondaryAdjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During Year 1 of the Double-blind Period

Adjusted mean change from baseline in British Isles Lupus Assessment Group (BILAG) score over time during Year 1 of the double-blind period based on a repeated measure mixed model and presented at each visit in the first 12-month of the double-blind period. BILAG index measures disease activity in different organs/systems separately. BILAG score is calculated for each of 9 systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. BILAG "A" represents the presence of serious features of lupus. BILAG "B" represents more moderate features of the disease. BILAG "C" includes only mild symptomatic features. BILAG "D" represents prior activity with no current symptoms due to active lupus. BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.

Time frame:
Day 1 to Day 365
Reported as:
Mean · Scores on a Scale
Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During Year 1 of the Double-blind Period
Scores on a ScaleAbatacept IVPlacebo IV
Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During Year 1 of the Double-blind Period-8.22 (-9.29 to -7.16)-7.60 (-8.66 to -6.54)
SecondaryNumber of Participants With Any Adverse Events (AEs) During Year 1 of the Double-blind Period

All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.

Time frame:
From Day 1 up to 56 days post last dose in Year 1 of the double-blind period
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AEs) During Year 1 of the Double-blind Period
ParticipantsAbatacept IVPlacebo IV
Participants with Adverse Events188194
Participants with Serious Adverse Events4939
Participants with infection Adverse Events150147
Participants with malignancies21
Participants with autoimmune events109
Participants with peri-infusional Adverse Events79
Participants with acute infusional Adverse Events24
SecondaryPercentage of Participants With Ranked Outcome of Complete Renal Response, Partial Renal Response (PR), and No Renal Response (NR) During the Double-blind Period

Complete Renal Response or Complete Response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; UPCR \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment. Partial Renal Response or Partial Response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was greater than or equal to 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment. No Renal Response or No Response (NR): defined as not meeting criteria for CR or PR or withdrawn

Time frame:
Day 365, Day 729
Reported as:
Number · Percentage
Percentage of Participants With Ranked Outcome of Complete Renal Response, Partial Renal Response (PR), and No Renal Response (NR) During the Double-blind Period
PercentageAbatacept IVPlacebo IV
CR - Day 36535.133.5
PR - Day 36520.821.7
NR - Day 36544.144.8
CR - Day 72960.753.6
PR - Day 72925.922.7
NR - Day 72913.423.6
Statistical analysis
  • Abatacept IV vs Placebo IV · Estimate of difference: 1.6510 · 95% CI -7.595828 to 10.897784
  • Abatacept IV · Estimate of difference: -0.8828 · 95% CI -8.848056 to 7.082461
  • Abatacept IV vs Placebo IV · Estimate of difference: -0.7682 · 95% CI -10.446714 to 8.910353
SecondaryMedian Time to Complete Renal Response During the Double-blind Period in All Participants

The estimate of median time to Complete Renal Response is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.

Time frame:
Day 365, Day 729
Reported as:
Median · Days
Median Time to Complete Renal Response During the Double-blind Period in All Participants
DaysAbatacept IVPlacebo IV
Day 365280.0 (198.0 to 365.0)309.0 (280.0 to 365.0)
Day 729170.0 (141.0 to 225.0)282.0 (225.0 to 357.0)
SecondaryMedian Time to Complete Renal Response During the Double-blind Period in Nephrotic Participants

The estimate of median time to Complete Renal Response in nephrotic participants is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.

Time frame:
Day 365, Day 729
Reported as:
Median · Days
Median Time to Complete Renal Response During the Double-blind Period in Nephrotic Participants
DaysAbatacept IVPlacebo IV
Day 365366.0 (337.0 to NA)368.0 (311.0 to 368.0)
Day 729365.0 (197.0 to 644.0)368.0 (308.0 to 505.0)
SecondaryMedian Time to Partial Renal Response During the Double-blind Period in All Participants

The estimate of median time to Partial Response (PR) is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment

Time frame:
Day 365, Day 729
Reported as:
Median · Days
Median Time to Partial Renal Response During the Double-blind Period in All Participants
DaysAbatacept IVPlacebo IV
Day 365226.0 (198.0 to 313.0)253.0 (198.0 to 358.0)
Day 72959.0 (56.0 to 85.0)58.0 (57.0 to 85.0)
SecondaryMedian Time to Partial Renal Response During the Double-blind Period in Nephrotic Participants

The estimate of median time to Partial Response (PR) in nephrotic participants is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment

Time frame:
Day 365, Day 729
Reported as:
Median · Days
Median Time to Partial Renal Response During the Double-blind Period in Nephrotic Participants
DaysAbatacept IVPlacebo IV
Day 365225.0 (196.0 to 311.0)196.0 (170.0 to 225.0)
Day 72958.5 (29.0 to 86.0)56.0 (29.0 to 58.0)
SecondaryAdjusted Mean Change From Baseline in UPCR Over Time

A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used.

Time frame:
Day 365; Day 729, includes data up to July 1st 2017 when double-blind therapy ended
Reported as:
Mean · UPCR (mg/mg)
Adjusted Mean Change From Baseline in UPCR Over Time
UPCR (mg/mg)Abatacept IVPlacebo IV
Day 365-2.95 ± 0.17-2.68 ± 0.17
Day 729-3.13 ± 0.18-2.72 ± 0.18
SecondaryMedian Percent Change From Baseline in UPCR Over Time

A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used. % Change from Baseline = (post baseline - baseline value) / baseline value x 100

Time frame:
Day 365, Day 729
Reported as:
Median · Percent
Median Percent Change From Baseline in UPCR Over Time
PercentAbatacept IVPlacebo IV
Day 365-83.77 (-92.42 to -64.18)-84.12 (-94.03 to -59.98)
Day 729-89.83 (-95.41 to -77.95)-87.28 (-93.78 to -66.43)
SecondaryAdjusted Mean Change From Baseline in eGFR Over Time

Estimated glomerular filtration rate(eGFR), will be calculated by the CKD-EPI formula shown below.50 eGFR is expressed as mL/min per 1.73m2. For the purpose of this study lower limit of normal eGFR is defined as 90mL/min per 1.73m2 eGFR = 141 X min (Scr/k, 1)α X max (Scr/k, 1)-1.209 X 0.993Age X (1.018 \[if female\]) X (1.159 \[if black\]) Where Scr is serum creatinine (mg/dL), k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1, age in years.

Time frame:
Day 365, Day 729
Reported as:
Mean · mL/min per 1.73m2
Adjusted Mean Change From Baseline in eGFR Over Time
mL/min per 1.73m2Abatacept IVPlacebo IV
Day 3656.85 (3.47 to 10.23)5.85 (2.51 to 9.20)
Day 7297.20 (3.40 to 11.00)7.91 (4.14 to 11.68)
SecondaryMedian Time to First Sustained Change to No Response During the Double-blind Period

Sustained response defined as response present at 2 consecutive visits approximately 4 weeks apart. No renal response (NR): defined as not meeting criteria for CR or PR or withdrawn The estimate of median time is based on Kaplan-Meier analysis

Time frame:
Day 365, Day 729
Reported as:
Median · Days
Median Time to First Sustained Change to No Response During the Double-blind Period
DaysAbatacept IVPlacebo IV
Day 365NA (392.0 to NA)NA (NA to NA)
Day 729NA (NA to NA)NA (672.0 to NA)
SecondaryNumber of Participants With Sustained Change From Higher Level of Response to no Response During the Double-blind Period

Sustained change to no response is defined as going from CR (or PR) to NR and remaining in NR for at least 2 consecutive visits; visits should be approximately 4 weeks apart. This analysis will be based on time from response CR (or PR) to the first visit in which the no response (NR) was achieved and sustained to the next visit.

Time frame:
Day 365, Day 729
Reported as:
Number · Participants
Number of Participants With Sustained Change From Higher Level of Response to no Response During the Double-blind Period
ParticipantsAbatacept IVPlacebo IV
Day 36553
Day 7295256
Statistical analysis
  • Abatacept IV vs Placebo IV · Hazard ratio (hr): 1.43 · 95% CI 0.3251 to 6.2849
  • Abatacept IV vs Placebo IV · Estimate of difference vs drug: 3.4 · 95% CI -8.4 to 15.1
SecondaryAdjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During the Double-blind Period

BILAG index measures and reports disease activity in different organs/systems separately. The BILAG score is calculated for each of nine systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. A BILAG "A" represents the presence of one or more serious features of lupus. A BILAG "B" represents more moderate features of the disease. A BILAG "C" includes only mild symptomatic features. A BILAG "D" represents only prior activity with no current symptoms due to active lupus. A BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.

Time frame:
Day 1 to Day 729; Day 365 to Day 729
Reported as:
Mean · Scores on a Scale
Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During the Double-blind Period
Scores on a ScaleAbatacept IVPlacebo IV
Day 1 to Day 729-9.31 ± 0.56-8.53 ± 0.56
Day 365 to Day 729-0.95 ± 0.538-0.40 ± 0.530
SecondaryCmin (ug/mL): Trough Level Serum Concentration of Abatacept Prior to the Administration of the IV Infusion

Trough level serum concentration of abatacept prior to the administration of the IV infusion on Days 1 to 365

Time frame:
Days 1 to 365
Reported as:
Geometric mean · ug/mL
Cmin (ug/mL): Trough Level Serum Concentration of Abatacept Prior to the Administration of the IV Infusion
ug/mLAbatacept IVPlacebo IV
Day 1569.97 ± 91.4—
Day 2990.46 ± 56.8—
Day 5736.43 ± 84.4—
Day 8534.46 ± 55.4—
Day 11316.42 ± 69.2—
Day 16913.98 ± 64.5—
Day 28114.44 ± 54.7—
Day 33714.99 ± 73.6—
Day 36513.62 ± 51.7—
SecondaryCmax: Maximum Observed Serum Concentration Following Participants Receiving Active Abatacept IV

Cmax: Maximum observed serum concentration following participants receiving active abatacept IV

Time frame:
at 1 hour post Day 1 dose and 30 minutes post Day 337 dose
Reported as:
Geometric mean · ug/mL
Cmax: Maximum Observed Serum Concentration Following Participants Receiving Active Abatacept IV
ug/mLAbatacept IVPlacebo IV
Day 1527.43 ± 59.6—
Day 337203.51 ± 30.6—
SecondaryAUC (TAU): Area Under the Serum Concentration Time Curve Over a Dosing Interval

AUC (TAU): Area under the serum concentration time curve over a dosing interval between Days 337 to 365.

Time frame:
Days 337 to 365
Reported as:
Geometric mean · ug*h/mL
AUC (TAU): Area Under the Serum Concentration Time Curve Over a Dosing Interval
ug*h/mLAbatacept IVPlacebo IV
AUC (TAU): Area Under the Serum Concentration Time Curve Over a Dosing Interval36480.24 ± 29.2—
SecondarySummary Statistics for Systolic Blood Pressure

Summary statistics for systolic blood pressure

Time frame:
Day 1 to Day 729
Reported as:
Mean · mmHg
Summary Statistics for Systolic Blood Pressure
mmHgAbatacept IVPlacebo IV
Day 1, end of observation122.0 ± 15.48122.6 ± 15.31
Day 365, end of observation112.3 ± 18.45115.0 ± 7.07
Day 729, end of observation108.6 ± 13.29114.2 ± 14.51
SecondarySummary Statistics for Diastolic Blood Pressure

Summary statistics for diastolic blood pressure

Time frame:
Day 1 to Day 729
Reported as:
Mean · mmHg
Summary Statistics for Diastolic Blood Pressure
mmHgAbatacept IVPlacebo IV
Day 1, end of observation76.5 ± 11.4977.0 ± 11.19
Day 365, end of observation73.5 ± 10.7577.5 ± 10.61
Day 729, end of observation67.5 ± 9.6072.7 ± 9.45
SecondarySummary Statistics for Heart Rate

Summary statistics for Heart Rate

Time frame:
Day 1 to Day 729
Reported as:
Mean · beats per minute
Summary Statistics for Heart Rate
beats per minuteAbatacept IVPlacebo IV
Day 1, end of observation80.6 ± 10.9181.4 ± 10.64
Day 365, end of observation78.5 ± 9.5770.0 ± 14.14
Day 729, end of observation76.2 ± 11.6976.7 ± 10.36
SecondaryMean Change From Baseline in Laboratory Analytes During the Double-blind Period (U/L)

Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Day 729
Reported as:
Mean · U/L
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (U/L)
U/LAbatacept IVPlacebo IV
ALANINE AMINOTRANSFERASE (ALT) (U/L)-2.2 (-4.834 to 0.382)-3.4 (-6.462 to -0.435)
ALKALINE PHOSPHATASE (ALP) (U/L)8.2 (4.514 to 11.967)11.7 (7.125 to 16.202)
ASPARTATE AMINOTRANSFERASE (AST) (U/L)0.3 (-1.747 to 2.288)0.3 (-1.326 to 1.947)
G-GLUTAMYL TRANSFERASE (GGT) (U/L)-5.3 (-11.020 to 0.509)-4.1 (-11.419 to 3.143)
SecondaryMean Change From Baseline in Laboratory Analytes During the Double-blind Period (g/L)

Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Day 729
Reported as:
Mean · g/L
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (g/L)
g/LAbatacept IVPlacebo IV
ALBUMIN (g/L)9.2 (8.040 to 10.336)8.1 (6.917 to 9.308)
HEMOGLOBIN (g/L)8.8 (5.977 to 11.574)9.0 (5.480 to 12.449)
PROTEIN, TOTAL (g/L)9.9 (8.135 to 11.579)10.1 (8.438 to 11.786)
SecondaryMean Change From Baseline in Laboratory Analytes During the Double-blind Period (Percentage of Blood)

Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Day 729
Reported as:
Mean · Percentage
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Percentage of Blood)
PercentageAbatacept IVPlacebo IV
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Percentage of Blood)0.0328 (0.023873 to 0.041658)0.0325 (0.021813 to 0.043160)
SecondaryMean Change From Baseline in Laboratory Analytes During the Double-blind Period (Umol/L)

Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Day 729
Reported as:
Mean · umol/L
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Umol/L)
umol/LAbatacept IVPlacebo IV
BILIRUBIN, TOTAL (umol/L)1.77 (1.0751 to 2.4633)1.00 (0.5112 to 1.4922)
CREATININE (umol/L)-5.6 (-9.306 to -1.912)-6.2 (-10.764 to -1.598)
SecondaryMean Change From Baseline in Laboratory Analytes During the Double-blind Period (mmol/L)

Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Day 729
Reported as:
Mean · mmol/L
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (mmol/L)
mmol/LAbatacept IVPlacebo IV
BLOOD UREA NITROGEN (mmol/L)-2.31 (-2.9879 to -1.6241)-2.25 (-2.8370 to -1.6682)
CALCIUM, TOTAL (mmol/L)0.097 (0.06893 to 0.12566)0.108 (0.07754 to 0.13850)
CHLORIDE, SERUM (mmol/L)-1.1 (-1.675 to -0.461)-0.5 (-1.244 to 0.192)
GLUCOSE, SERUM (mmol/L)-0.23 (-0.4924 to 0.0424)-0.58 (-0.9623 to -0.1902)
PHOSPHORUS, INORGANIC (mmol/L)-0.077 (-0.12699 to -0.02654)-0.037 (-0.08152 to 0.00807)
POTASSIUM, SERUM (mmol/L)-0.02 (-0.0947 to 0.0646)-0.10 (-0.2115 to 0.0029)
SODIUM, SERUM (mmol/L)-0.2 (-0.762 to 0.280)-0.5 (-1.060 to 0.078)
SecondaryMean Change From Baseline in Laboratory Analytes During the Double-blind Period (x10^9 Cells/L)

Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Day 729
Reported as:
Mean · x10^9 cells/L
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (x10^9 Cells/L)
x10^9 cells/LAbatacept IVPlacebo IV
EOSINOPHILS (ABSOLUTE) (x10^9 cells/L)0.034 (0.01182 to 0.05611)0.010 (-0.01781 to 0.03781)
LYMPHOCYTES (ABSOLUTE) (x10^9 cells/L)0.141 (-0.01315 to 0.29584)-0.149 (-0.29961 to 0.00138)
MONOCYTES (ABSOLUTE) (x10^9 cells/L)-0.018 (-0.05220 to 0.01649)-0.050 (-0.09264 to -0.00772)
NEUTROPHILS (ABSOLUTE) (x10^9 cells/L)-2.259 (-2.78568 to -1.73210)-2.289 (-2.95652 to -1.62118)
PLATELET COUNT (x10^9 cells/L)-4.9 (-16.962 to 7.148)-9.1 (-24.094 to 5.951)
SecondaryNumber of Participants With Marked Hematology Laboratory Abnormalities During Year 1 of the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Reported as:
Number · participants
Number of Participants With Marked Hematology Laboratory Abnormalities During Year 1 of the Double Blind Period
participantsAbatacept IVPlacebo IV
HEMOGLOBIN, low610
HEMOGLOBIN, highNANA
HEMATOCRIT, low1212
HEMATOCRIT, highNANA
ERYTHROCYTES, low710
ERYTHROCYTES, highNANA
PLATELET COUNT, low43
PLATELET COUNT, high00
LEUKOCYTES, low3521
LEUKOCYTES, high2925
EOSINOPHILS (ABSOLUTE), lowNANA
EOSINOPHILS (ABSOLUTE), high26
BASOPHILS (ABSOLUTE), lowNANA
BASOPHILS (ABSOLUTE), high11
MONOCYTES (ABSOLUTE), lowNANA
MONOCYTES (ABSOLUTE), high01
LYMPHOCYTES (ABSOLUTE), low81104
LYMPHOCYTES (ABSOLUTE), high12
SecondaryNumber of Participants With Marked Liver and Kidney Function Laboratory Abnormalities During Year 1 of the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Reported as:
Number · participants
Number of Participants With Marked Liver and Kidney Function Laboratory Abnormalities During Year 1 of the Double Blind Period
participantsAbatacept IVPlacebo IV
ALKALINE PHOSPHATASE (ALP), lowNANA
ALKALINE PHOSPHATASE (ALP), high11
ASPARTATE AMINOTRANSFERASE (AST), lowNANA
ASPARTATE AMINOTRANSFERASE (AST), high50
ALANINE AMINOTRANSFERASE (ALT), lowNANA
ALANINE AMINOTRANSFERASE (ALT), high82
G-GLUTAMYL TRANSFERASE (GGT), lowNANA
G-GLUTAMYL TRANSFERASE (GGT), high1715
BILIRUBIN, TOTAL, lowNANA
BILIRUBIN, TOTAL, high00
BILIRUBIN, DIRECT, lowNANA
BILIRUBIN, DIRECT, high00
BLOOD UREA NITROGEN, lowNANA
BLOOD UREA NITROGEN, high2012
CREATININE, lowNANA
CREATININE, high2420
SecondaryNumber of Participants With Marked Electrolyte Laboratory Abnormalities During Year 1 of the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Reported as:
Number · participants
Number of Participants With Marked Electrolyte Laboratory Abnormalities During Year 1 of the Double Blind Period
participantsAbatacept IVPlacebo IV
SODIUM, SERUM, low11
SODIUM, SERUM, high22
POTASSIUM, SERUM, low35
POTASSIUM, SERUM, high77
CHLORIDE, SERUM, low01
CHLORIDE, SERUM, high00
CALCIUM, TOTAL, low11
CALCIUM, TOTAL, high20
PHOSPHORUS, INORGANIC, low97
PHOSPHORUS, INORGANIC, high1313
SecondaryNumber of Participants With Marked Urinalysis Laboratory Abnormalities During Year 1 of the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4

Time frame:
Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Reported as:
Number · participants
Number of Participants With Marked Urinalysis Laboratory Abnormalities During Year 1 of the Double Blind Period
participantsAbatacept IVPlacebo IV
PROTEIN, URINE, lowNANA
PROTEIN, URINE, high00
GLUCOSE, URINE, lowNANA
GLUCOSE, URINE, high00
BLOOD, URINE, lowNANA
BLOOD, URINE, high00
Red blood cells (RBC), URINE, lowNANA
Red blood cells (RBC), URINE, high93103
White blood cells (WBC), URINE, lowNANA
White blood cells (WBC), URINE, high9198
SecondaryNumber of Participants With Other Marked Chemistry Laboratory Abnormalities During Year 1 of the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Reported as:
Number · participants
Number of Participants With Other Marked Chemistry Laboratory Abnormalities During Year 1 of the Double Blind Period
participantsAbatacept IVPlacebo IV
GLUCOSE, SERUM, low3329
GLUCOSE, SERUM, high105
PROTEIN, TOTAL, low4426
PROTEIN, TOTAL, high01
ALBUMIN, low1011
ALBUMIN, highNANA
SecondaryNumber of Participants With Any Adverse Events (AEs) During Year 2 of the Double-blind Period and Long-term Extension

All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.

Time frame:
From the first dose in Year 2 of the double-blind period up to 56 days post last dose
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AEs) During Year 2 of the Double-blind Period and Long-term Extension
ParticipantsAbatacept IVPlacebo IV
Participants with Adverse Events127137
Participants with Serious Adverse Events1525
Participants with infection Adverse Events100107
Participants with malignancies01
Participants with autoimmune events711
SecondaryPercentage of Participants in Treatment Failure Over Time During the Double-blind Period

Lupus treatment failure is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor.

Time frame:
Day 365, Day 729
Reported as:
Number · Percentage
Percentage of Participants in Treatment Failure Over Time During the Double-blind Period
PercentageAbatacept IVPlacebo IV
Lupus treatment failure (LTF) - Day 3653.5 (0.943 to 5.988)4.4 (1.602 to 7.265)
Overall treatment failure (OTF) - Day 3654.5 (1.610 to 7.301)4.9 (1.949 to 7.903)
LTF - Day 7294.5 (1.0 to 8.0)5.3 (1.5 to 9.2)
OTF - Day 7295.2 (1.5 to 9.0)8.4 (3.6 to 13.1)
Statistical analysis
  • Abatacept IV vs Placebo IV · Estimate of difference: -0.9682 · 95% CI -4.760178 to 2.823876
  • Abatacept IV · Estimate of difference: -0.4707 · 95% CI -4.588691 to 3.647365
  • Abatacept IV vs Placebo IV · Estimate of difference: 0.8 · 95% CI -4.5 to 6.1
  • Abatacept IV vs Placebo IV · Estimate of difference: 2.7 · 95% CI -3.3 to 8.8
SecondaryMedian Time to First Treatment Failure and Overall Treatment Failure During the Double-blind Period

First treatment failure (or Lupus treatment failure) is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor. The hazard ratio is estimated using the Cox proportional hazards model which includes treatment group, stratification variables (baseline ACEis/ARBs use, RACE) and baseline UPCR. The estimate of median time is based on Kaplan-Meier analysis

Time frame:
Day 365, Day 729
Reported as:
Median · Days
Median Time to First Treatment Failure and Overall Treatment Failure During the Double-blind Period
DaysAbatacept IVPlacebo IV
First treatment failure (FTF) - Day 365NA (NA to NA)NA (NA to NA)
Overall treatment failure (OTF) - Day 365NA (NA to NA)NA (NA to NA)
FTF - Day 729NA (NA to NA)NA (NA to NA)
OTF - Day 729NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period

Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.

Time frame:
Day 729
Reported as:
Number · Percentage
Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period
PercentageAbatacept IVPlacebo IV
Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period50.049.0
SecondaryPercentage of Participants in Overall Population in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period

Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.

Time frame:
Day 729
Reported as:
Number · Percentage
Percentage of Participants in Overall Population in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period
PercentageAbatacept IVPlacebo IV
Percentage of Participants in Overall Population in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period61.952.7
SecondaryNumber of Participants With Marked Hematology Laboratory Abnormalities in the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 729
Reported as:
Number · participants
Number of Participants With Marked Hematology Laboratory Abnormalities in the Double Blind Period
participantsAbatacept IVPlacebo IV
HEMOGLOBIN, low89
HEMOGLOBIN, highNANA
HEMATOCRIT, low62
HEMATOCRIT, highNANA
ERYTHROCYTES, low42
ERYTHROCYTES, highNANA
PLATELET COUNT, low24
PLATELET COUNT, high10
LEUKOCYTES, low1924
LEUKOCYTES, high35
EOSINOPHILS (ABSOLUTE), lowNANA
EOSINOPHILS (ABSOLUTE), high116
BASOPHILS (ABSOLUTE), lowNANA
BASOPHILS (ABSOLUTE), high00
MONOCYTES (ABSOLUTE), lowNANA
MONOCYTES (ABSOLUTE), high00
LYMPHOCYTES (ABSOLUTE), low4362
LYMPHOCYTES (ABSOLUTE), high00
SecondaryNumber of Participants With Marked Liver and Kidney Function Laboratory Abnormalities in the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 729
Reported as:
Number · participants
Number of Participants With Marked Liver and Kidney Function Laboratory Abnormalities in the Double Blind Period
participantsAbatacept IVPlacebo IV
ALKALINE PHOSPHATASE (ALP), lowNANA
ALKALINE PHOSPHATASE (ALP), high40
ASPARTATE AMINOTRANSFERASE (AST), lowNANA
ASPARTATE AMINOTRANSFERASE (AST), high23
ALANINE AMINOTRANSFERASE (ALT), lowNANA
ALANINE AMINOTRANSFERASE (ALT), high43
G-GLUTAMYL TRANSFERASE (GGT), lowNANA
G-GLUTAMYL TRANSFERASE (GGT), high1711
BILIRUBIN, TOTAL, lowNANA
BILIRUBIN, TOTAL, high00
BILIRUBIN, DIRECT, lowNANA
BILIRUBIN, DIRECT, high10
BLOOD UREA NITROGEN, lowNANA
BLOOD UREA NITROGEN, high109
CREATININE, lowNANA
CREATININE, high1716
SecondaryNumber of Participants With Marked Electrolyte Laboratory Abnormalities in the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 729
Reported as:
Number · participants
Number of Participants With Marked Electrolyte Laboratory Abnormalities in the Double Blind Period
participantsAbatacept IVPlacebo IV
SODIUM, SERUM, low00
SODIUM, SERUM, high01
POTASSIUM, SERUM, low22
POTASSIUM, SERUM, high32
CHLORIDE, SERUM, low01
CHLORIDE, SERUM, high00
CALCIUM, TOTAL, low00
CALCIUM, TOTAL, high10
PHOSPHORUS, INORGANIC, low34
PHOSPHORUS, INORGANIC, high63
SecondaryNumber of Participants With Marked Urinalysis Laboratory Abnormalities in the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4

Time frame:
Day 1 to Day 729
Reported as:
Number · participants
Number of Participants With Marked Urinalysis Laboratory Abnormalities in the Double Blind Period
participantsAbatacept IVPlacebo IV
PROTEIN, URINE, lowNANA
PROTEIN, URINE, high00
GLUCOSE, URINE, lowNANA
GLUCOSE, URINE, high00
BLOOD, URINE, lowNANA
BLOOD, URINE, high00
Red blood cells (RBC), URINE, lowNANA
Red blood cells (RBC), URINE, high5855
White blood cells (WBC), URINE, lowNANA
White blood cells (WBC), URINE, high4659
SecondaryNumber of Participants With Other Marked Chemistry Laboratory Abnormalities in the Double Blind Period

LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte

Time frame:
Day 1 to Day 729
Reported as:
Number · participants
Number of Participants With Other Marked Chemistry Laboratory Abnormalities in the Double Blind Period
participantsAbatacept IVPlacebo IV
GLUCOSE, SERUM, low1524
GLUCOSE, SERUM, high32
GLUCOSE, FASTING SERUM, low31
GLUCOSE, FASTING SERUM, high31
PROTEIN, TOTAL, low107
PROTEIN, TOTAL, high23
ALBUMIN, low45
ALBUMIN, highNANA
SecondaryNumber of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period

Participants who experienced a positive antibody response relative to baseline (ECL Assay)

Time frame:
Day 365, Day 729
Reported as:
Number · Participants
Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period
ParticipantsAbatacept IVPlacebo IV
Day 365, overall79

Adverse events

Collected over From Day 1 up to 56 days post last dose (assessed up to May 2018, approximately 66 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept IV7/202 (3.5%)62/202 (30.7%)164/202 (81.2%)
Placebo IV6/203 (3%)58/203 (28.6%)179/203 (88.2%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventAbatacept IVPlacebo IV
PneumoniaInfections and infestations15/2026/203
Herpes zosterInfections and infestations5/2024/203
OsteonecrosisMusculoskeletal and connective tissue disorders1/2025/203
Lupus nephritisRenal and urinary disorders4/2022/203
Urinary tract infectionInfections and infestations1/2024/203
AnaemiaBlood and lymphatic system disorders3/2022/203
PregnancyPregnancy, puerperium and perinatal conditions3/2020/203
EncephalitisInfections and infestations2/2020/203
GastroenteritisInfections and infestations2/2022/203
Genital herpesInfections and infestations2/2020/203
Most frequent other events
Showing 10 of 26
Most frequent other events
EventAbatacept IVPlacebo IV
DiarrhoeaGastrointestinal disorders47/20246/203
Urinary tract infectionInfections and infestations45/20238/203
NasopharyngitisInfections and infestations40/20244/203
Upper respiratory tract infectionInfections and infestations43/20242/203
BronchitisInfections and infestations18/20226/203
CoughRespiratory, thoracic and mediastinal disorders25/20224/203
HeadacheNervous system disorders24/20223/203
PharyngitisInfections and infestations20/20224/203
AnaemiaBlood and lymphatic system disorders20/20223/203
ArthralgiaMusculoskeletal and connective tissue disorders21/20219/203

Baseline characteristics

All Randomized and Treated Subjects

Age, Continuous
Age, Continuous(years)Abatacept IVPlacebo IVTotal
Mean33.1 ± 10.7533.2 ± 10.4833.1 ± 10.60
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept IVPlacebo IVTotal
Female182178360
Male202545
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abatacept IVPlacebo IVTotal
Asian7174145
African American151530
Caucasian8571156
Other314374
08

Study locations

149 sites
  • University Of Alabama At Birmingham (Uab)
    Birmingham, Alabama 35294, United States
  • Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
    Long Beach, California 90806, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • University Of Connecticut Health Center
    Farmington, Connecticut 06030, United States
  • University Of Miami Miller School Of Medicine
    Miami, Florida 33136, United States
  • Integral Rheumatology & Immunology Specialists
    Plantation, Florida 33324, United States
  • Emory University.
    Atlanta, Georgia 30303, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Ochsner Clinic Foundation
    Baton Rouge, Louisiana 70809, United States
  • Tulane University School Of Medicine
    New Orleans, Louisiana 70112, United States
  • Brigham & Women'S Hospital
    Boston, Massachusetts 02115, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • Local Institution
    Camden, New Jersey 08103, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203-2056, United States
  • Northshore Lij Health System
    Great Neck, New York 11021, United States
  • The Feinstein Institute For Medical Research
    Manhasset, New York 11030, United States
  • Hospital For Special Surgery
    New York, New York 10021-4892, United States
  • Local Institution
    New York, New York 10032, United States
  • University Of North Carolina At Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Shanahan Rheum & Immunotherapy, PLLC
    Raleigh, North Carolina 27617, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Paramount Medical Research & Consulting, Llc
    Middleburg Heights, Ohio 44130, United States
  • Rheumatology Consultants Pllc
    Knoxville, Tennessee 37909-1907, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University Of Utah Hospital
    Salt Lake City, Utah 84112, United States
  • Local Institution
    Charlottesville, Virginia 22908, United States
  • Organizacion Medica De Investigacion S.A. (Omi)
    Capital Federal, Buenos Aires 1015, Argentina
  • Local Institution
    Capital Federal, Buenos Aires 1431, Argentina
  • Local Institution
    Buenos Aires, 1181, Argentina
  • Hospital Privado-Centro Medico De Cordoba S.A.
    Cordoba, 5016, Argentina
  • Local Institution
    Adelaide, South Australia 5000, Australia
  • Local Institution
    Parkville, Victoria 3050, Australia
  • Local Institution
    Perth, Western Australia 6009, Australia
  • Local Institution
    Savaldor, Bahia 40150-150, Brazil
  • Local Institution
    Goiania, Goias 74110-120, Brazil
  • Local Institution
    Belo Horizonte, Minas Gerais 30150-320, Brazil
  • Local Institution
    Juiz De Fora, Minas Gerais 36010-570, Brazil
  • Local Institution
    Uberlandia, Minas Gerais 38400-902, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 91610000, Brazil
  • Local Institution
    Sao Paulo, 01323-900, Brazil
  • Local Institution
    Mississauga, Ontario L5M 2V8, Canada
  • Local Institution
    Toronto, Ontario M5T 2S8, Canada
  • Local Institution
    Santiago De Chile, Metropolitana 8360156, Chile
  • Local Institution
    Santiago, Metropolitana 8330024, Chile
  • Local Institution
    Independencia, Santiago, Chile
  • Local Institution
    Vina Del Mar, Valparaiso 2570017, Chile
  • Local Institution
    Beijing, Beijing 100034, China
  • Local Institution
    Beijing, Beijing 100044, China
  • Local Institution
    Guangzhou, Guangdong 510080, China
  • Local Institution
    Haikou, Hainan 570311, China
  • Local Institution
    Wuhan, Hebei 430030, China
  • Local Institution
    Harbin, Heilongjiang 150001, China
  • Local Institution
    Zhengzhou, Henan 450004, China
  • Local Institution
    Wuxi, Jiangsu 214023, China
  • Local Institution
    Nanchang, Jiangxi, China
  • Local Institution
    Xian, Shan1xi 710054, China
  • Local Institution
    Shanghai, Shanghai 200032, China
  • Local Institution
    Chengdu, Sichuan 610041, China
  • Local Institution
    Hangzhou, Zhejiang 310003, China
  • Local Institution
    Beijing, 100029, China
  • Local Institution
    Chong Qing, 400010, China
  • Local Institution
    Guangzhou, China
  • Local Institution
    Nanchang, 330006, China
  • Local Institution
    Nanning, 530000, China
  • Local Institution
    Shanghai, 200001, China
  • Local Institution
    Shanghai, 200025, China
  • Local Institution
    Shanghai, China
  • Local Institution
    Xi'An, China
  • Riesgo De Fractura S.A. Cayre Ips
    Bogota, Cundinamarca, Colombia
  • Servimed E.U
    Bucaramanga, Santander, Colombia
  • Clinica De La Costa
    Barranquilla, XXXXXX, Colombia
  • Circaribe S.A.S
    Barranquilla, Colombia
  • Hospital Universitario San Ignacio
    Bogota, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, MEDELLIN, Colombia
  • Local Institution
    Praha 2, 128 50, Czechia
  • Local Institution
    Hong Kong, Hong Kong
  • Local Institution
    Secunderabad, Andhra Pradesh 500003, India
  • Local Institution
    Ahmedabad, Gujrat 380052, India
  • Local Institution
    Gurgaon, 122001, India
  • Local Institution
    Hyderabad, 500004, India
  • Local Institution
    Lucknow-, 226018, India
  • Local Institution
    New Delhi, 110029, India
  • Local Institution
    Haifa, 31048, Israel
  • Local Institution
    Haifa, 31096, Israel
  • Local Institution
    Ramat-gan, Israel
  • Local Institution
    Tel Aviv, 64239, Israel
  • Local Institution
    Brescia, 25123, Italy
  • Local Institution
    Milano, 20122, Italy
  • Local Institution
    Padova, 35128, Italy
  • Local Institution
    Reggio Emilia, 42100, Italy
  • Local Institution
    Torino, 10128, Italy
  • Local Institution
    Nagakute-shi, Aichi 4801195, Japan
  • Local Institution
    Nagoya-shi, Aichi 4668560, Japan
  • Local Institution
    Chiba-shi, Chiba 2608677, Japan
  • Local Institution
    Fukuoka-shi, Fukuoka 8108563, Japan
  • Local Institution
    Kitakyushu-shi, Fukuoka 8078555, Japan
  • Local Institution
    Maebashi-shi, Gunma 3718511, Japan
  • Local Institution
    Sapporo-shi, Hokkaido 0608604, Japan
  • Local Institution
    Sapporo-shi, Hokkaido, Japan
  • Local Institution
    Kanazawa-shi, Ishikawa 9208641, Japan

Showing the first 100 of 149 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Nov 2016, 45 months.

Results were first posted in Dec 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2012
First posted
Oct 26, 2012
StartActual
Jan 22, 2013
Primary completionActual
Nov 21, 2016
CompletionActual
May 30, 2018
Results first posted
Dec 21, 2017
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01714817
Responsible party
Sponsor
First posted
Oct 26, 2012
Start date
Jan 22, 2013
Primary completion
Nov 21, 2016
Completion
May 30, 2018
Results posted
Dec 21, 2017
Last update
Feb 26, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion